GENE ONLINE|News &
Opinion
Blog

CAR-T Cell
Atara Biotherapeutics’ First-In-Class Allogeneic T-Cell Therapy Accepted for EMA Review
2021-12-02
China’s Legend Biotech to Build a CAR-T Therapy Production Site in Belgium
2021-06-24
Blackstone Pumps $250 Million in CAR-T Startup, Betting on Intellia’s and Cellex’s Technologies
2021-06-23
Bristol-Myers Faces Lawsuit Claims Over Side-Stepping $6.4 Billion CVR Payment
2021-06-04
CAR-M Therapy – Trojan Horse for Solid Cancer Treatment?
2021-04-05
BMS, bluebird’s Multiple Myeloma Drug Becomes First BCMA Targeting CAR-T Therapy to Snag FDA Okay
2021-03-28
Aiming for the First CAR-T Approval in China, JW Therapeutics Debuts on Hong Kong Stock Exchange
2020-11-04
CRISPR Therapeutics’ CAR-T Cell Therapy Registers Mixed Results in Cancer Trial
2020-10-23
China-Based Immunotherapy Company Receives FDA’s Orphan Drug Designation for Advanced Gastric Cancer Treatment
2020-10-07
Novartis’ Kymriah Headed Towards Third Approval for Follicular Lymphoma
2020-08-06
New Frontiers in Therapeutics
2020-07-25Partner
Cas – CLOVER: A New Dawn in Genome Editing Technology
2020-07-13
BMS, bluebird bio’s Investigational BCMA CAR-T Therapy Faces Regulatory Setback
2020-05-18
CAR-T Therapy – a Boon for Cancer Treatment?
2020-04-27
Korean Biotech, AbClon Enters Trials with New CAR-T Molecule against Ovarian Cancer
2020-04-23
1 2 3
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top